Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment

被引：62
作者：
Voican, C. S. [1 ]
Mir, O. [2 ]
Loulergue, P. [3 ]
Dhooge, M. [1 ]
Brezault, C. [1 ]
Dreanic, J. [1 ]
Chaussade, S. [1 ]
Pol, S. [4 ,5 ]
Coriat, R. [1 ]
机构：
[1] Univ Paris 05, Cochin Teaching Hosp, AP HP, Gastroenterol & Digest Oncol Unit,Sorbonne Paris, Paris, France
[2] Dept Canc Med, Gustave Roussy Canc Campus, Villejuif, France
[3] Univ Paris 05, Sorbonne Paris Cite, Cochin Teaching Hosp, AP HP,CIC Vaccinol, Paris, France
[4] Univ Paris 05, Sorbonne Paris Cite, Cochin Teaching Hosp, AP HP,Hepatol Unit, Paris, France
[5] Inst Pasteur, INSERM, USM20, Paris, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 12期
关键词：
chemotherapy; solid tumors; hepatitis B reactivation; tyrosine kinase inhibitors; monoclonal antibodies; immunotherapy; ANTIGEN-NEGATIVE PATIENT; BREAST-CANCER PATIENTS; CHEMOTHERAPY-INDUCED REACTIVATION; TENOFOVIR DISOPROXIL FUMARATE; MYELOID-LEUKEMIA PATIENT; SURFACE-ANTIGEN; CYTOTOXIC CHEMOTHERAPY; PREEMPTIVE LAMIVUDINE; HBV REACTIVATION; PHASE-II;
D O I：
10.1093/annonc/mdw414
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Hepatitis B virus (HBV) reactivation is a well-known risk during chemotherapy for hematological malignancies with reported rates ranging between 14% and 72%. However, there is a paucity of data regarding HBV infection management and reactivation risk in patients receiving systemic treatments for solid tumors. Design: We conducted a PubMed search for publications from January 1990 until May 2016 related to HBV reactivation. The search terms were 'hepatitis B reactivation', cross-referenced with 'chemotherapy', then 'hepatitis B' cross-referenced with International Non-proprietary Name of each of the most used chemotherapy drugs in solid tumors. Results: From these data, a grading of HBV reactivation risk and recommendations for management are given for most frequently used anticancer drugs in solid tumors. Conclusion: Most drugs used for the treatment of solid tumors can induce hepatitis B reactivation in HBs antigen-positive patients. HBV screening can be recommended before systemic treatment initiation. Pre-emptive antiviral treatment can reduce the risk of HBV reactivation and prevent chemotherapy disruption.
引用
收藏
页码：2172 / 2184
页数：14
相关论文
共 92 条
[1]  
Ahmed A, 1999, AM J GASTROENTEROL, V94, P249, DOI 10.1111/j.1572-0241.1999.00808.x
[2]   Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours [J].
Alexopoulos, CG ;
Vaslamatzis, W ;
Hatzidimitriou, G .
BRITISH JOURNAL OF CANCER, 1999, 81 (01) :69-74
[3]   Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].
Allen, MI ;
Deslauriers, M ;
Andrews, CW ;
Tipples, GA ;
Walters, KA ;
Tyrrell, DLJ ;
Brown, N ;
Condreay, LD .
HEPATOLOGY, 1998, 27 (06) :1670-1677
[4]  
Alvino E, 1998, ANTICANCER RES, V18, P3597
[5]  
Cainelli F, 2001, AM J GASTROENTEROL, V96, P1651
[6]   Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients [J].
Cheng, JCH ;
Liu, MC ;
Tsai, SY ;
Fang, WT ;
Jian, JJM ;
Sung, JL .
CANCER, 2004, 101 (09) :2126-2133
[7]   Gemcitabine and reactivation of hepatitis B [J].
Cheong, K ;
Li, J ;
Karapetis, CS .
MEDICAL ONCOLOGY, 2003, 20 (04) :385-387
[8]   Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma [J].
Clark, FL ;
Drummond, MW ;
Chambers, S ;
Chapman, BA ;
Patton, WN .
ANNALS OF ONCOLOGY, 1998, 9 (04) :385-387
[9]   Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells [J].
Coenen, J. J. A. ;
Koenen, H. J. P. M. ;
van Rijssen, E. ;
Kasran, A. ;
Boon, L. ;
Hilbrands, L. B. ;
Joosten, I. .
BONE MARROW TRANSPLANTATION, 2007, 39 (09) :537-545
[10]   Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration [J].
Dai, MS ;
Wu, PF ;
Shyu, RY ;
Lu, JJ ;
Chao, TY .
LIVER INTERNATIONAL, 2004, 24 (06) :540-546
12345678910